ストックスクリーナーアプリを入手
235.22
1.05%
-2.96
前日終値:
$238.18
開ける：
$237.1
24時間の取引高:
238.09K
Relative Volume:
0.73
時価総額：
$6.67B
収益：
$2.58B
当期純損益:
$-778.69M
株価収益率:
-8.6067
EPS:
-27.33
ネットキャッシュフロー:
$223.75M
1週間 パフォーマンス:
-5.58%
1か月 パフォーマンス:
-8.18%
6か月 パフォーマンス:
-31.31%
1年 パフォーマンス:
-15.75%
1日の値動き範囲:
$232.53
$238.79
1週間の範囲:
$232.53
$250.74
52週間の値動き範囲:
$215.38
$387.99
Bio Rad Laboratories Inc Stock (BIO) Company Profile
名前
Bio Rad Laboratories Inc
セクター
電話
(510) 724-7000
住所
1000 ALFRED NOBEL DRIVE, HERCULES
BIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
235.46 | 6.67B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
129.24 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
93.34 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
338.00 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
81.41 | 105.92B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
68.97 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-01 | アップグレード | Citigroup | Neutral → Buy |
| 2024-08-28 | 開始されました | Wells Fargo | Equal Weight |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2024-04-03 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-12-07 | 開始されました | UBS | Buy |
| 2023-06-16 | 開始されました | Wells Fargo | Overweight |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-01-28 | 繰り返されました | Citigroup | Buy |
| 2020-01-08 | 開始されました | Wells Fargo | Overweight |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2018-10-17 | 開始されました | Goldman | Buy |
| 2018-09-20 | 開始されました | Morgan Stanley | Equal-Weight |
| 2018-02-16 | ダウングレード | CL King | Buy → Neutral |
| 2017-07-13 | 開始されました | Wells Fargo | Outperform |
| 2017-06-28 | アップグレード | Deutsche Bank | Hold → Buy |
| 2017-01-18 | 開始されました | Deutsche Bank | Hold |
| 2016-10-13 | 開始されました | CL King | Buy |
| 2015-05-06 | 繰り返されました | Jefferies | Buy |
| 2009-12-18 | 開始されました | Maxim Group | Buy |
| 2009-11-06 | 開始されました | Jefferies & Co | Buy |
| 2009-07-17 | 開始されました | Soleil | Buy |
| 2007-09-26 | 開始されました | Banc of America Sec | Buy |
| 2007-02-23 | ダウングレード | Robert W. Baird | Outperform → Neutral |
すべてを表示
Bio Rad Laboratories Inc (BIO) 最新ニュース
Digital Pcr And Real-Time PCR Market Deep Research Report with - openPR.com
Should You be Optimistic on Bio-Rad Laboratories’s (BIO) Outlook? - Insider Monkey
Industrial Microbiology Market Set to Witness Significant - openPR.com
Fecal Calprotectin Test Market Overall Study Report 2025-2032 | - openPR.com
Surface Plasmon Resonance Market Is Booming Worldwide 2025-2032 | Bio-Rad Laboratories, Inc., Carterra Inc. - openPR.com
Drug Abuse Testing Market Forecast Report and Company Analysis 2025-2033 Featuring Danaher, LabCorp, Abbott, Quest Diagnostics, Thermo Fisher Scientific, F. Hoffmann-La Roche, Bio-Rad Labs, Medtronic - Yahoo
Biochips Market Set to Witness Significant Growth by 2023 | - openPR.com
Chromatography Market to Reach $14.37 Billion, Globally, by 2032 at 5.3% CAGR: Coherent Market Insights - GlobeNewswire Inc.
Biodetection Market Detailed In New Research Report 2025 | Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc. - openPR.com
Lobbying Update: $80,000 of BIO-RAD LABORATORIES lobbying was just disclosed - Nasdaq
Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 - BioSpace
Bio-Rad to Report First Quarter 2025 Financial Results on Thursd - GuruFocus
Bio-Rad To Report First Quarter 2025 Financial Results On Thursday, May 1, 2025 - marketscreener.com
Cancer Monoclonal Antibodies Market Projected To Witness - openPR.com
Sickle Cell Anemia Testing and Screening Market Detailed In New - openPR.com
Next Generation Sequencing (NGS) Market Growth, Trends & - openPR.com
Enzyme Linked Immunosorbent Assay Market Set for Significant - openPR.com
US Biomarkers Market worth $34.3 billion in 2029 - The Globe and Mail
Porphyria Treatment Market Detailed In New Research Report 2025 - openPR.com
Helicobacter Pylori Diagnostics Market Is Booming Worldwide | Thermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc. - openPR.com
Flow Cytometry Market Analysis: Trends, Growth, and Forecast - openPR.com
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Protein Assays Market Outlook: Growth Drivers and Future - openPR.com
Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)? - simplywall.st
Hemoglobinopathy Market Trends, Innovations, Growth & - openPR.com
Industrial Microbiology Market Future Business Opportunities - openPR.com
New Horizons in Microbiome Sample Preparation Technology - openPR.com
Polymerase Chain Reaction Market Projected To Witness - openPR.com
Enhancing Process Development with Viral Clearance: mAb Purification With a Weak AEX-HIC Chromatography Resin - BioProcess International
Clinical Biomarkers Market Key Players Analysis- QIAGEN, - openPR.com
RBC Cuts Price Target on Bio-Rad Laboratories to $409 From $430, Keeps Outperform Rating - marketscreener.com
Laboratory Supplies Market Projected To Witness Substantial - openPR.com
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
High End Cellomics Market Generated Opportunities, Future - openPR.com
Laboratory Proficiency Testing Market Deep Research 2025-2032 - openPR.com
Polyclonal Antibody Market Expansion | Drug Development & - openPR.com
Biodetection Market to Witness Stunning Growth with Bio-Rad - openPR.com
Learn to Evaluate (BIO.B) using the Charts - news.stocktradersdaily.com
US Single-Cell Analysis Market to Reach $2,695.3 Billion by 2029 - The Globe and Mail
Biosensors Market Is Booming Worldwide | Bio-Rad Laboratories - openPR.com
Digital Pcr And Real Time Pcr (Qpcr) Market Deep Research Report - openPR.com
Further weakness as Bio-Rad Laboratories (NYSE:BIO) drops 5.0% this week, taking three-year losses to 61% - Yahoo Finance
Bio-Rad stock touches 52-week low at $234.81 amid market shifts By Investing.com - Investing.com South Africa
Bio Rad Laboratories Inc (BIO) 財務データ
収益
当期純利益
現金流量
EPS
0.81%
1.34%
大文字化:
|
ボリューム (24 時間):